Quince Therapeutics Statistics
Total Valuation
QNCX has a market cap or net worth of $45.38 million. The enterprise value is -$15.93 million.
Market Cap | 45.38M |
Enterprise Value | -15.93M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, after market close.
Earnings Date | May 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
QNCX has 43.22 million shares outstanding. The number of shares has increased by 11.17% in one year.
Shares Outstanding | 43.22M |
Shares Change (YoY) | +11.17% |
Shares Change (QoQ) | +14.00% |
Owned by Insiders (%) | 17.06% |
Owned by Institutions (%) | 28.16% |
Float | 27.05M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.53 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.09, with a Debt / Equity ratio of 0.16.
Current Ratio | 8.09 |
Quick Ratio | n/a |
Debt / Equity | 0.16 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -36.40% and return on invested capital (ROIC) is -33.43%.
Return on Equity (ROE) | -36.40% |
Return on Assets (ROA) | -28.80% |
Return on Capital (ROIC) | -33.43% |
Revenue Per Employee | n/a |
Profits Per Employee | -$980,781 |
Employee Count | 32 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | -197,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.05% in the last 52 weeks. The beta is 1.25, so QNCX's price volatility has been higher than the market average.
Beta (1Y) | 1.25 |
52-Week Price Change | -29.05% |
50-Day Moving Average | 1.17 |
200-Day Moving Average | 1.17 |
Relative Strength Index (RSI) | 46.34 |
Average Volume (30 Days) | 68,579 |
Short Selling Information
The latest short interest is 1.86 million, so 4.30% of the outstanding shares have been sold short.
Short Interest | 1.86M |
Short Previous Month | 1.86M |
Short % of Shares Out | 4.30% |
Short % of Float | 6.87% |
Short Ratio (days to cover) | 37.67 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -33.04M |
Pretax Income | -31.58M |
Net Income | -31.39M |
EBITDA | -31.26M |
EBIT | -31.58M |
Earnings Per Share (EPS) | -$0.84 |
Balance Sheet
The company has $75.06 million in cash and $13.75 million in debt, giving a net cash position of $61.31 million or $1.42 per share.
Cash & Cash Equivalents | 75.06M |
Total Debt | 13.75M |
Net Cash | 61.31M |
Net Cash Per Share | $1.42 |
Equity / Book Value | 85.08M |
Book Value Per Share | 1.97 |
Working Capital | 67.87M |
Cash Flow
In the last 12 months, operating cash flow was -$18.29 million and capital expenditures -$70,000, giving a free cash flow of -$18.36 million.
Operating Cash Flow | -18.29M |
Capital Expenditures | -70,000 |
Free Cash Flow | -18.36M |
FCF Per Share | -$0.49 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
QNCX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -11.17% |
Shareholder Yield | -11.17% |
Earnings Yield | -69.17% |
FCF Yield | -40.47% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |